SCHEMBL3073015

SCHEMBL3073015

CC(C)(C)OC(=O)N1C=C(Br)C=CC1C1CCNCC1

nearest known ligand 0.33

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 6/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
KDM4E B2RXH2 1/20 0.32
MAPT P10636 1/20 0.32
THRB P10828 1/20 0.32
MAPK1 P28482 1/20 0.32
HDAC1 Q13547 1/20 0.32
NR1H2 P55055 1/20 0.32
UCHL1 P09936 1/20 0.31
GLA P06280 1/20 0.31
PLAT P00750 1/20 0.31
CHRM2 P08172 1/20 0.31
CHRM1 P11229 1/20 0.31
CHRM3 P20309 1/20 0.31
ABL1 P00519 1/20 0.31
RIN1 Q13671 1/20 0.31
ELANE P08246 1/20 0.31
PREP P48147 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4242556 0.85 MEN1 (0.35) GPR119MEN1KMT2AKDM4EMAPT
SCHEMBL4236595 0.76 GPR119 (0.32) GPR119KDM4EMAPTTHRBNR1H2
SCHEMBL3456238 0.75 GPR119 (0.35) GPR119NR1H2
SCHEMBL3454833 0.74 GPR119 (0.48) GPR119KDM4E
SCHEMBL6833620 0.70 GPR119 (0.32) GPR119KDM4EMAPTTHRBNR1H2
SCHEMBL16963472 0.67 NR1H2 (0.59) GPR119MEN1KMT2AKDM4EMAPT
SCHEMBL16963473 0.67 NR1H2 (0.59) GPR119MEN1KMT2AKDM4EMAPT
SCHEMBL2811594 0.66 KDM4E (0.34) GPR119MEN1KMT2AKDM4EMAPT
SCHEMBL10175516 0.66 NR1H2 (0.58) GPR119KDM4EMAPTTHRBNR1H2
Hydrochloric Acid SCHEMBL16052766 0.66 NR1H2 (0.58) GPR119MEN1KMT2AKDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8344001-B2 Heterocyclic H3 antagonists HIGH POINT PHARMACEUTICALS, LLC (US) 2013-01-01 US disclosed
US-20100267721-A1 Heterocyclic H3 Antagonists HIGH POINT PHARMACEUTICALS LLC (US) 2010-10-21 US disclosed
EP-2166850-A1 NEW HETEOCYCLIC H3 ANTAGONISTS High Point Pharmaceuticals, LLC (US) 2010-03-31 EP disclosed
WO-2008154126-A1 NEW HETEOCYCLIC H3 ANTAGONISTS HIGH POINT PHARMACEUTICALS, LLC (US) 2008-12-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100267721-A1 Heterocyclic H3 Antagonists HRH3, HRH4, HRH2 GPR119 398/4885MEN1 3067/4885KMT2A 865/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.